Ann: Investor Presentation - FY19 Results, page-2

For me, the outlook for FY20 is the Main message going forward

 In the absence of any significant deterioration in economic conditions, PROBIOTEC is forecasting revenuesto exceed $100 million and EBITDA in the range of $16 million to $17 million for FY20

 The key growth drivers are: • Full-year impact of newly contracted work; • Organic and new product growth from existing customers;
• The acquisition of ABS; • Cost savings from the development of 85 Cherry Lane (expected completion in September 2019)

M /Cap of around 100m with Estimated 16.5m in Ebitda that is a multiple of 6 x. they seem to execute their plan very well.
Div is going up, and the share buyback is in place in case the SP drifts lower.

I see PBP as a Long Term investment, steady growth and surprises on the upside in the last few years ( since G. Pearce the new chairman joined the company and bought a substantial amount of shares in the comp )